Product Name :
IOWH-032
Description:
IOWH032 is a CFTR inhibitor. Diarrhea, a disease of poverty and poor sanitation, kills an estimated two million children each year. Oral rehydration therapy is a very simple and inexpensive treatment that has significantly reduced mortality from secretory diarrhea caused by rotavirus, cholera and enterotoxigenic Escherichia coli. The efficacy and adoption of oral rehydration therapy would be enhanced by a drug that reduces fluid loss associated with these diseases and alleviates disease symptoms. Secretion and absorption by the intestine offer a number of potential drug targets to reduce fluid loss.
CAS:
1191252-49-9
Molecular Weight:
545.18
Formula:
C22H15Br2N3O4
Chemical Name:
3-(3,5-dibromo-4-hydroxyphenyl)-N-[(4-phenoxyphenyl)methyl]-1,2,4-oxadiazole-5-carboxamide
Smiles :
OC1C(Br)=CC(=CC=1Br)C1=NOC(=N1)C(=O)NCC1C=CC(=CC=1)OC1C=CC=CC=1
InChiKey:
DSFNLJXHXBIKDS-UHFFFAOYSA-N
InChi :
InChI=1S/C22H15Br2N3O4/c23-17-10-14(11-18(24)19(17)28)20-26-22(31-27-20)21(29)25-12-13-6-8-16(9-7-13)30-15-4-2-1-3-5-15/h1-11,28H,12H2,(H,25,29)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{FX-11} web|{FX-11} Reactive Oxygen Species|{FX-11} Purity & Documentation|{FX-11} Description|{FX-11} manufacturer|{FX-11} Epigenetics}
Shelf Life:
≥360 days if stored properly.{{GDNF Protein, Human} site|{GDNF Protein, Human} Protocol|{GDNF Protein, Human} Purity|{GDNF Protein, Human} custom synthesis|{GDNF Protein, Human} Autophagy}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
IOWH032 is a CFTR inhibitor. Diarrhea, a disease of poverty and poor sanitation, kills an estimated two million children each year.PMID:23460641 Oral rehydration therapy is a very simple and inexpensive treatment that has significantly reduced mortality from secretory diarrhea caused by rotavirus, cholera and enterotoxigenic Escherichia coli. The efficacy and adoption of oral rehydration therapy would be enhanced by a drug that reduces fluid loss associated with these diseases and alleviates disease symptoms. Secretion and absorption by the intestine offer a number of potential drug targets to reduce fluid loss.|Product information|CAS Number: 1191252-49-9|Molecular Weight: 545.18|Formula: C22H15Br2N3O4|Chemical Name: 3-(3,5-dibromo-4-hydroxyphenyl)-N-[(4-phenoxyphenyl)methyl]-1,2,4-oxadiazole-5-carboxamide|Smiles: OC1C(Br)=CC(=CC=1Br)C1=NOC(=N1)C(=O)NCC1C=CC(=CC=1)OC1C=CC=CC=1|InChiKey: DSFNLJXHXBIKDS-UHFFFAOYSA-N|InChi: InChI=1S/C22H15Br2N3O4/c23-17-10-14(11-18(24)19(17)28)20-26-22(31-27-20)21(29)25-12-13-6-8-16(9-7-13)30-15-4-2-1-3-5-15/h1-11,28H,12H2,(H,25,29)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|